B/FTC/TAF — Competitive Intelligence Brief

B/FTC/TAF (B/FTC/TAF) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antiretroviral combination (integrase inhibitor + nucleoside/nucleotide reverse transcriptase inhibitors). Area: Infectious Disease / Virology.

marketed Antiretroviral combination (integrase inhibitor + nucleoside/nucleotide reverse transcriptase inhibitors) HIV integrase, HIV reverse transcriptase Infectious Disease / Virology Small molecule

Target snapshot

B/FTC/TAF (B/FTC/TAF) — The University of Texas Health Science Center, Houston. B/FTC/TAF is a fixed-dose combination antiretroviral that inhibits HIV reverse transcriptase and integrase to prevent viral replication.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
B/FTC/TAF TARGET	B/FTC/TAF	The University of Texas Health Science Center, Houston	marketed	Antiretroviral combination (integrase inhibitor + nucleoside/nucleotide reverse transcriptase inhibitors)	HIV integrase, HIV reverse transcriptase
Raltegravir and Abacavir/Lamivudine	Raltegravir and Abacavir/Lamivudine	Denver Infectious Disease Consultants, PLLC	marketed	Antiretroviral combination (INSTI + NRTI)	HIV integrase, HIV reverse transcriptase
Biktarvy 50/200/25 Tab	Biktarvy 50/200/25 Tab	Radboud University Medical Center	marketed	Antiretroviral combination (integrase inhibitor + nucleotide/nucleoside reverse transcriptase inhibitors)	HIV integrase, HIV reverse transcriptase
Switch to B/F/TAF	Switch to B/F/TAF	University of Nairobi	marketed	Antiretroviral combination (integrase inhibitor + nucleoside/nucleotide reverse transcriptase inhibitors)	HIV integrase, HIV reverse transcriptase
ELV/COBI/FTC/TAF	ELV/COBI/FTC/TAF	Fundacion SEIMC-GESIDA	marketed	Antiretroviral combination therapy (integrase inhibitor + NRTI + NtRTI + pharmacokinetic booster)	HIV integrase, HIV reverse transcriptase
bictegravir/emtricitabine/tenofovir alafenamide	bictegravir/emtricitabine/tenofovir alafenamide	Midland Research Group, Inc.	marketed	Antiretroviral combination (integrase inhibitor + nucleoside reverse transcriptase inhibitors)	HIV integrase, HIV reverse transcriptase
DTG/ABC/3TC	DTG/ABC/3TC	Harvard School of Public Health (HSPH)	marketed	Antiretroviral combination therapy (integrase inhibitor + nucleoside reverse transcriptase inhibitors)	HIV integrase, HIV reverse transcriptase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antiretroviral combination (integrase inhibitor + nucleoside/nucleotide reverse transcriptase inhibitors) class)

1. The University of Texas Health Science Center, Houston · 1 drug in this class
2. University of Nairobi · 1 drug in this class